#USA #Houston #AI Drug Discovery #Sino Biological #4RISE™

Sino Biological Launches 4RISE™ High-Throughput Wet-Lab Services

In a revolutionary step towards enhancing drug discovery, Sino Biological, Inc. has announced the launch of its 4RISE™ high-throughput wet-lab services. This innovative initiative is designed specifically for the validation of AI-generated protein binders, which require rigorous testing to confirm their effectiveness in targeting specific biomolecules.

Sino Biological, recognized as a leader in recombinant technology, aims to bridge the gap between AI-designed proteins and practical applications in clinical settings. The new services offer a rapid 3-hour cell-free expression of proteins, with the capability to generate AI-ready binding data in as little as 3 days. This accelerated process enables life sciences researchers to significantly hasten their research cycles and gain deeper insights into their findings.

Transforming the Research Landscape

The XPressMAX™ Cell-Free Protein Synthesis (CFPS) platform is at the heart of this initiative. It allows for nearly instantaneous recombinant protein synthesis with a remarkable success rate exceeding 99%. This cutting-edge technology supports a variety of protein formats, including miniproteins, VHHs, scFvs, Fabs, enzymes, and cytokines, thus broadening the scope for experimental testing of AI-designed protein candidates.

Utilizing advanced techniques such as Carterra high-throughput Surface Plasmon Resonance (SPR), Biacore SPR, and Octet Bio-Layer Interferometry (BLI), the 4RISE™ workflow facilitates high-throughput binding screening, kinetic analysis, and affinity determination for candidate proteins. The seamless integration of CFPS and advanced screening methods enables researchers to obtain structured binding data that can be accessed in real-time via API, allowing for efficient downstream analysis and research progression.

Comprehensive Screening Services

4RISE™ boasts a flexible array of workflows tailored to suit varying research needs in AI-driven binder discovery. Among its offerings:

• - Rapid Hit Discovery for efficiently identifying binding-positive miniproteins and VHHs through initial crude-supernatant screening.
• - Comparative Binder Screening where purified candidates are evaluated under standardized conditions, assisting in the prioritization process.
• - Affinity Kinetic Characterization to provide quantitative insights essential for selecting lead candidates.
• - Specialized Binder Expression Validation, ensuring that various binder formats undergo rigorous testing with tailored mammalian expression and binding analysis.

Beyond binding assessments, 4RISE™ includes over 20 developability assays, 1,000+ protein bioactivity assays, and 10+ cell-based functional assays that support a comprehensive evaluation of protein candidates and drive further design optimization.

Proven Expertise and Real-World Impact

Sino Biological has extensive collaborations with numerous AI-driven companies, facilitating wet-lab validation for AI-designed antibody discovery and computational protein engineering. The data gleaned from 4RISE™ wet-lab validations have underpinned studies published in prestigious journals such as Science, Nature Communications, and Scientific Reports.

As Dr. Rob Burgess, Chief Business Officer at Sino Biological US, aptly stated, "AI-designed molecules need reliable wet-lab experimental evidence to demonstrate their potential. Our integrated capabilities provide the high-quality data researchers need to evaluate candidates quickly, shorten design cycles, and bring promising discoveries to market."

In this fast-paced era of drug discovery, Sino Biological's 4RISE™ service is a game-changer, offering life sciences researchers the tools they need to validate and harness the power of AI-driven solutions in drug development better than ever before.

Explore 4RISE™ and its promising capabilities on Sino Biological's official website today!